COMP <GO>
MDCX vs XTLB // REVENUE GROWTH (YOY)
Medicus Pharma Ltd. (NASDAQ) VS. XTL Biopharmaceuticals Ltd. (NASDAQ) • 15-METRIC TALLY: MDCX 0
— XTLB 2
■ METRIC PARITY
LAST: $2.15 (-13.31%) • MKT CAP: $4.1M
revenue-growth
—
LAST: $1.76 (-12.44%) • MKT CAP: $4.3M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDCX VS. XTLB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDCX | XTLB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 16.6 | 33.8 | -17.19 | XTLB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.1M | $4.3M | -$257.7K | XTLB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDCX REV | XTLB REV | MDCX GROSS % | XTLB GROSS % | MDCX FCF | XTLB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | — | — | — | -$22.8M | — |
| FY 2024 | $0 | — | — | — | -$10.2M | — |
| FY 2023 | $0 | — | — | — | -$4.2M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDCX // BETA —
XTLB // BETA —